摘要
目的:探讨曲妥珠单抗联合伊沙匹隆治疗晚期转移性乳腺癌的疗效。方法:纳入我院收治的92例HER-2阳性晚期乳腺癌患者,其中对照组(45例)单用曲妥珠单抗治疗,研究组(47例)采用曲妥珠单抗联合伊沙匹隆治疗,比较两组临床疗效。结果:研究组的治疗总有效率明显高于对照组,差异具有统计学意义(P<0.05),两组的疾病控制率比较,研究组疾病控制率明显高于对照组,差异具有统计学意义(P<0.05);治疗前,两组患者血清肿瘤标志物水平比较,差异无统计学意义(P>0.05),治疗后,两组患者血清肿瘤标志物水平均较治疗前有所降低,同组与治疗前比较,差异具有统计学意义(P<0.05),同时研究组患者治疗后的血清肿瘤标志物水平明显低于对照组,差异具有统计学意义(P<0.05);治疗后统计两组患者的用药不良反应以及程度,结果显示两组患者不良反应率比较,差异无统计学意义(P>0.05)。结论:采用曲妥珠单抗联合伊沙匹隆治疗晚期转移性乳腺癌患者的临床疗效较佳,可降低CEA、CA125及CA15-3水平,且用药安全,具有临床推广价值。
Objective：To investigate the efficacy of trastuzumab in combination with ixabepilone treatment of advanced metastatic breast cancer. Methods： 92 patients with HER-2 positive advanced breast cancer patients in our hospital were selected, the control group （45 cases） with trastuzumab treatment, study group （47 cases ） with trastuzumab combined with ixabepilone treatment. The clinical efficacy was compared between the two groups. Results： After treatment, the total effective rate of treatment group was significantly higher than the control group, the difference was statistically significant （P 〈 0.05 ） ; For the disease control rate of two groups, disease control rate of study group was significantly higher than the control group, the difference was statistically significant （P 〈 0.05 ） ; For the patients of two groups before treatment, the level of serum tumor markers in comparison, no statistically significant difference （P 〉 0.05） ; after treatment, patients with serum levels of tumor markers of two groups were lower than before treatment ; compared with the group before treatment, the difference was statistically significant （P 〈 0.05） ; while the serum tumor research after treatment the levels of markers was significantly lower than the control group, the difference was statistically significant （P 〈 0.05） ; There was no statistically significant difference in adverse reaction rates between the two groups （P 〉 0.05 ）. Conclusion： Trastuzumab combined with ixabepilone for patients with metastatic breast cancer can reduce the CEA, CA125 and CA15-3 levels, and drug safety, has clinical value.
出处
《河北医学》
CAS
2017年第10期1598-1602,共5页
Hebei Medicine
基金
黑龙江省卫生和计划生育委员会科研课题
(编号:2016-004)
